What Smart Money Thinks about BioCryst Pharmaceuticals, Inc. (BCRX)?

Now, some big names were leading the bulls’ herd. Deerfield Management initiated the biggest position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). Behzad Aghazadeh’s venBio Select Advisor also made a $6.1 million investment in the stock during the third quarter. The other funds with new positions in the stock are Israel Englander’s Millennium Management, Hal Mintz’s Sabby Capital, and Peter Muller’s PDT Partners.

Let’s check out hedge fund activity in other stocks similar to BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). These stocks are Merchants Bancshares,Inc. (NASDAQ:MBVT), Comtech Telecomm. Corp. (NASDAQ:CMTL), Lifetime Brands Inc (NASDAQ:LCUT), and RTI Biologics Inc. (NASDAQ:RTIX). This group of stocks’ market caps match BCRX’s market cap.

As you can see these stocks had an average of seven investors with bullish positions and the average amount invested in these stocks was $23 million. That figure was $123 million in BCRX’s case. RTI Biologics Inc. (NASDAQ:RTIX) is the most popular stock in this table. On the other hand Merchants Bancshares,Inc. (NASDAQ:MBVT) is the least popular one with only two bullish hedge fund positions. Compared to these stocks BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.

Disclosure: None